|Articles|September 1, 2017
- Pharmaceutical Executive-09-01-2017
- Volume 37
- Issue 9
Pharmaceutical Executive, September 2017 Issue (PDF)
Click the title above to open the Pharmaceutical Executive September 2017 issue in an interactive PDF format.
Advertisement
Articles in this issue
about 8 years ago
Pharm Exec's 16th Annual Industry Auditabout 8 years ago
The Supply Chain: What Price Patient Centricity?about 8 years ago
Drug Serialization for DSCSA Compliance Benefits Everyoneabout 8 years ago
Pharm Exec's 16th Annual Industry Audit (Overview)over 8 years ago
You Are Pharmaover 8 years ago
Leading With Patients in Mind: Cynthia Schwalmover 8 years ago
FDA, Industry Prepare for New User Fee Initiativesover 8 years ago
Data Inflection Pointover 8 years ago
UK Unveils Post-Brexit Life Sciences Strategyover 8 years ago
Seizing the Opportunity in STEMNewsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Mark Cuban Pushes for Generic Drug Fee Waivers, as Cost Plus Drugs Eyes US Manufacturing Expansion
2
Pharmaceutical Executive Daily: FDA Names Tracy Beth Høeg as Acting Director of CDER
3
FDA Appoints Tracy Beth Høeg as Acting Director of CDER
4
FDA Approves Breyanzi for Adults with Relapsed or Refractory Marginal Zone Lymphoma
5
